FDA Approves Lilly's Ebglyss (lebrikizumab-lbkz) for One Maintenance Dose Every Eight Weeks in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 18, 2026 - 17:00
 0  0
INDIANAPOLIS, June 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of Ebglyss...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0